Literature DB >> 11595987

West Nile encephalitis: an emerging disease in the United States.

A A Marfin1, D J Gubler.   

Abstract

In 1999, an epidemic of West Nile virus (WNV) encephalitis occurred in New York City (NYC) and 2 surrounding New York counties. Simultaneously, an epizootic among American crows and other bird species occurred in 4 states. Indigenous transmission of WNV had never been documented in the western hemisphere until this epidemic. In 2000, the epizootic expanded to 12 states and the District of Columbia, and the epidemic continued in NYC, 5 New Jersey counties, and 1 Connecticut county. In addition to these outbreaks, several large epidemics of WNV have occurred in other regions of the world where this disease was absent or rare >5 years ago. Many of the WNV strains isolated during recent outbreaks demonstrate an extremely high degree of homology that strongly suggests widespread circulation of potentially epidemic strains of WNV. The high rates of severe neurologic illness and death among humans, horses, and birds in these outbreaks are unprecedented and unexplained. We review the current status of WNV in the United States.

Entities:  

Mesh:

Year:  2001        PMID: 11595987     DOI: 10.1086/322700

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  56 in total

1.  Print media coverage of risk-risk tradeoffs associated with West Nile encephalitis and pesticide spraying.

Authors:  John P Roche
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

Review 2.  West Nile virus: a growing concern?

Authors:  L Hannah Gould; Erol Fikrig
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

3.  Glycosylation of the West Nile Virus envelope protein increases in vivo and in vitro viral multiplication in birds.

Authors:  Ryo Murata; Yuki Eshita; Akihiko Maeda; Junko Maeda; Saki Akita; Tomohisa Tanaka; Kentaro Yoshii; Hiroaki Kariwa; Takashi Umemura; Ikuo Takashima
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

4.  Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.

Authors:  Rex Biedenbender; Joan Bevilacqua; Anne M Gregg; Mike Watson; Gustavo Dayan
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

5.  Human Monoclonal Fab Antibodies Against West Nile Virus and its Neutralizing Activity Analyzed in Vitro and in Vivo.

Authors:  Tao Duan; Monique Ferguson; Lintian Yuan; Fangling Xu; Guangyu Li
Journal:  J Antivir Antiretrovir       Date:  2009-11-01

6.  Environmental and ecological determinants of West Nile virus occurrence in horses in North Dakota, 2002.

Authors:  M Ndiva Mongoh; M L Khaitsa; N W Dyer
Journal:  Epidemiol Infect       Date:  2006-06-06       Impact factor: 2.451

7.  Characterization of a West Nile virus isolate from a human on the Gulf Coast of Texas.

Authors:  Bruno P Granwehr; Li Li; Charles T Davis; David W C Beasley; Alan D T Barrett
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

8.  Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.

Authors:  Claire Y-H Huang; Shawn J Silengo; Melissa C Whiteman; Richard M Kinney
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 9.  West Nile Virus: biology, transmission, and human infection.

Authors:  Tonya M Colpitts; Michael J Conway; Ruth R Montgomery; Erol Fikrig
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

10.  A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.

Authors:  Nathalie Bonafé; Joseph A Rininger; Richard G Chubet; Harald G Foellmer; Stacey Fader; John F Anderson; Sandra L Bushmich; Karen Anthony; Michel Ledizet; Erol Fikrig; Raymond A Koski; Paul Kaplan
Journal:  Vaccine       Date:  2008-11-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.